Global Retinal Vein Occlusion Market 2014-2018

News provided by

Jul 28, 2014, 07:33 ET

LONDON, July 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Global Retinal Vein Occlusion Market 2014-2018

https://www.reportbuyer.com/product/2255167/Global-Retinal-Vein-Occlusion-Market-2014-2018.html

About Retinal Vein Occlusion
Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion.

TechNavio's analysts forecast the Global Retinal Vein Occlusion market will grow at a CAGR of 16.04 percent over the period 2013-2018.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Retinal Vein Occlusion market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of retinal vein occlusion.
TechNavio's report, the Global Retinal Vein Occlusion Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Retinal Vein Occlusion market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
- Americas
- EMEA
- APAC

Key Vendors
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Regeneron Pharmaceuticals Inc.

Other Prominent Vendors

- Alimera Sciences
- Bristol-Myers Squibb
- NicOx
- Santen Pharmaceutical Co.
- Valeant Pharmaceuticals International
Key Market Driver
- High Unmet Need
- For a full, detailed list, view our report.

Key Market Challenge
- Serious Adverse Side Effects
- For a full, detailed list, view our report.

Key Market Trend
- Introduction of Biologics
- For a full, detailed list, view our report.

Key Questions Answered in this Report
- What will the market size be in 2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
Product Portfolio
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Pipeline Portfolio
08. Rate of Incidence and Prevalence
09. Market Segmentation by Type of Therapy
09.1.1 Biologics
09.1.2 Corticosteroids
10. Market Segmentation by Route of Administration
10.1.1 Intravitreal
10.1.2 Intravenous
11. Market Segmentation by Dosage Forms
11.1.1 Solutions
11.1.2 Implant
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.2.1 Other Prominent Vendors
21. Key Vendor Analysis
21.1 Bayer
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation
21.1.4 Business Segmentation by Revenue 2012 and 2013
21.1.5 Sales by Geography
21.1.6 Business Strategy
21.1.7 Key Information
21.1.8 SWOT Analysis
21.1.9 Strengths
21.1.10 Weaknesses
21.1.11 Opportunities
21.1.12 Threats
21.2 Roche
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Business Strategy
21.2.7 Key Information
21.2.8 SWOT Analysis
21.2.9 Strengths
21.2.10 Weaknesses
21.2.11 Opportunities
21.2.12 Threats
21.3 Novartis
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue 2013
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Sales by Geography
21.3.6 Business Strategy
21.3.7 Key Developments
21.3.8 SWOT Analysis
21.3.9 Strengths
21.3.10 Weaknesses
21.3.11 Opportunities
21.3.12 Threats
21.4 Regeneron Pharmaceuticals
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Product Segmentation
21.4.4 Revenue Product Segmentation
21.4.5 Business Strategy
21.4.6 Key Information
21.4.7 SWOT Analysis
21.4.8 Strengths
21.4.9 Weaknesses
21.4.10 Opportunities
21.4.11 Threats
22. Other Reports in this Series

List of Exhibits

Exhibit 1: Market Research Methodology
Exhibit 2: Global Retinal Vein Occlusion Market 2013-2018 (US$ million)
Exhibit 3: Pipeline Portfolio of the Drugs for the Treatment of Retinal Vein Occlusion
Exhibit 4: Global Retinal Vein Occlusion Market by Type of Therapy
Exhibit 5: Global Retinal Vein Occlusion Market by Route of Administration
Exhibit 6: Global Retinal Vein Occlusion Market by Dosage Forms
Exhibit 7: Global Retinal Vein Occlusion Market by Geographical Segmentation
Exhibit 8: Global Retinal Vein Occlusion Market Share Analysis 2013
Exhibit 9: Product-wise Revenue Share in Global Retinal Vein Occlusion Market 2013
Exhibit 10: Bayer AG: Business Segmentation 2013
Exhibit 11: Bayer AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 12: Bayer AG: Sales by Geography 2013
Exhibit 13: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 14: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
Exhibit 15: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 16: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
Exhibit 17: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 18: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 19: Novartis AG: Sales by Geography 2013
Exhibit 20: Regeneron Pharmaceuticals Inc.: Product Segmentation
Exhibit 21: Regeneron Pharmaceuticals Inc.: Revenue Product Segmentation 2013